nach oben

Current HIV/AIDS Reports

Erschienen in:

19.01.2021 | Complications of HIV and Antiretroviral Therapy (GA McComsey, Section Editor)

Gastrointestinal Dysfunction and HIV Comorbidities

verfasst von: Jae H. Sim, Shibani S. Mukerji, Samuel C. Russo, Janet Lo

Erschienen in: Current HIV/AIDS Reports | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Gut dysfunction and resulting chronic low-grade inflammation have been linked to metabolic and chronic diseases in the general population. In this review, we present recently published studies of HIV-associated gut dysfunction and comorbidities including obesity, diabetes, cardiovascular disease, liver disease, and neurocognitive disease.

Recent Findings

Biomarkers of microbial translocation, dysbiosis, or intestinal epithelial integrity have been used to investigate relationships between HIV-associated gut dysfunction and metabolic, cardiovascular, and neurologic complications. Many studies point to worsened comorbidities associated with gut dysfunction in people with HIV (PWH), but some studies show mixed results, and thus, the data are still inconclusive and limited to surrogate biomarkers rather than direct intestinal assessments.

Summary

Inflammation and immune activation stemming from changes in intestinal epithelial integrity and dysbiosis are present in PWH and relate to metabolic, cardiovascular, and neurologic complications of HIV. However, future investigations, especially future studies that directly assess intestinal pathology, are needed to investigate the direct contributory role of gastrointestinal dysfunction to comorbidities of HIV.

Lerner AM, Eisinger RW, Fauci AS. Comorbidities in persons with HIV: the lingering challenge. JAMA. 2020;323(1):19–20.CrossRef

Gallant J, Hsue PY, Shreay S, Meyer N. Comorbidities Among US Patients with prevalent HIV infection—a trend analysis. J Infect Dis. 2017;216(12):1525–33.PubMed

Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006;12(12):1365–71.PubMedCrossRef

Sandler NG, Douek DC. Microbial translocation in HIV infection: causes, consequences and treatment opportunities. Nat Rev Microbiol. 2012;10(9):655–66.PubMedCrossRef

Sandler NG, Wand H, Roque A, Law M, Nason MC, Nixon DE, et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis. 2011;203(6):780–90.PubMedPubMedCentralCrossRef

Hunt PW, Sinclair E, Rodriguez B, Shive C, Clagett B, Funderburg N, et al. Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection. J Infect Dis. 2014;210(8):1228–38.PubMedPubMedCentralCrossRef

Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007;56(7):1761–72.PubMedCrossRef

Creely SJ, PG MT, Kusminski CM, Fisher FM, Da Silva NF, Khanolkar M, et al. Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. Am J Physiol-Endocrinol Metab. 2007;292(3):E740-E7.CrossRef

Pussinen PJ, Havulinna AS, Lehto M, Sundvall J, Salomaa V. Endotoxemia is associated with an increased risk of incident diabetes. Diabetes Care. 2011;34(2):392–7.PubMedPubMedCentralCrossRef

10.

Dabke K, Hendrick G, Devkota S. The gut microbiome and metabolic syndrome. J Clin Invest. 2019;129(10):4050–7.PubMedPubMedCentralCrossRef

11.

Pedersen KK, Pedersen M, Trøseid M, Gaardbo JC, Lund TT, Thomsen C, et al. Microbial translocation in HIV infection is associated with dyslipidemia, insulin resistance, and risk of myocardial infarction. J Acquir Immune Defic Syndr. 2013;64(5):9.CrossRef

12.

Timmons T, Shen C, Aldrovandi G, Rollie A, Gupta SK, Stein JH, et al. Microbial translocation and metabolic and body composition measures in treated and untreated HIV infection. AIDS Research and Human Retroviruses. 2014;30(3):272–7.PubMedPubMedCentralCrossRef

13.

Moreno-Pérez Ó, Giner L, Reus S, Boix V, Alfayate R, Frances R, et al. Impact of circulating bacterial DNA in long-term glucose homeostasis in non-diabetic patients with HIV infection: cohort study. Eur J Clin Microbiol Infect Dis. 2018;37(2):313–8.PubMedCrossRef

14.

Qin J, Li Y, Cai Z, Li S, Zhu J, Zhang F, et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. 2012;490(7418):55–60.PubMedCrossRef

15.

Hartstra AV, Bouter KEC, Bäckhed F, Nieuwdorp M. Insights into the role of the microbiome in obesity and type 2 diabetes. Diabetes Care. 2015;38(1):159–65.PubMedCrossRef

16.

• Dillon SM, Kibbie J, Lee EJ, Guo K, Santiago ML, Austin GL, et al. Low abundance of colonic butyrate-producing bacteria in HIV infection is associated with microbial translocation and immune activation. AIDS. 2017;31(4):511–21 This study demonstrated lower abundance of butyrate-producing bacteria, which are important for maintaining intestinal barrier function, in untreated PWH compared to individuals without HIV. In particular, the decreased abundance of Roseburia intestinalis correlated with markers of microbial translocation and immune activation.PubMedPubMedCentralCrossRef

17.

Mave V, Erlandson KM, Gupte N, Balagopal A, Asmuth DM, Campbell TB, et al. Inflammation and change in body weight with antiretroviral therapy initiation in a multinational cohort of HIV-infected adults. J Infect Dis. 2016;214(1):65–72.PubMedPubMedCentralCrossRef

18.

• El Kamari V, Moser C, Hileman CO, Currier JS, Brown TT, Johnston L, et al. Lower pretreatment gut integrity is independently associated with fat gain on antiretroviral therapy. Clin Infect Dis. 2019;68(8):1394–401 For the first time in PWH, this study showed an association between fat gain and gut dysfunction. Pre-ART I-FABP levels were significant associated with changes in body composition as measured by visceral adipose tissue, total adipose tissue, and body mass index over 96 weeks of ART treatment.PubMedCrossRef

19.

• Dirajlal-Fargo S, Moser C, Rodriguez K, El-Kamari V, Funderburg NT, Bowman E, et al. Changes in the fungal marker β-D-glucan after antiretroviral therapy and association with adiposity. Open Forum Infect Dis. 2019;6(11):ofz434 This study highlights the potential role of mycobiome and metabolic complications in PWH by demonstrating the association between fungal translocation marker β-D-glucan and excess trunk and total fat accumulation in PWH over 96 weeks of ART treatment.PubMedPubMedCentralCrossRef

20.

• Gogokhia L, Taur Y, Juluru K, Yagan N, Zhu Y-S, Pamer E, et al. Intestinal Dysbiosis and Markers of systemic inflammation in viscerally and generally obese persons living with HIV. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2020;83(1):81–9 This is the first study examining the intestinal dysbiosis by body habitus in PWH, showing that bacterial diversity measured by fecal 16S rDNA sequencing was reduced in visceral and general obesity compared with lean participants and was negatively correlated with sCD14.PubMedCrossRef

21.

Koethe JR, Grome H, Jenkins CA, Kalams SA, Sterling TR. The metabolic and cardiovascular consequences of obesity in persons with HIV on long-term antiretroviral therapy. AIDS. 2016;30(1):83–91.PubMedPubMedCentralCrossRef

22.

Taylor BS, So-Armah K, Tate JP, Marconi VC, Koethe JR, Bedimo RJ, et al. HIV and obesity comorbidity increase interleukin 6 but not soluble CD14 or D-dimer. J Acquir Immune Defic Syndr. 2017;75(5):500–8.PubMedPubMedCentralCrossRef

23.

Leung C, Rivera L, Furness JB, Angus PW. The role of the gut microbiota in NAFLD. Nat Rev Gastroenterol Hepatol. 2016 Jul;13(7):412–25.PubMedCrossRef

24.

Verna EC. Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in patients with HIV. Lancet Gastroenterol Hepatol. 2017;2(3):211–23.PubMedCrossRef

25.

Balagopal A, Philp FH, Astemborski J, Block TM, Mehta A, Long R, et al. Human immunodeficiency virus-related microbial translocation and progression of hepatitis C. Gastroenterology. 2008;135(1):226–33.PubMedPubMedCentralCrossRef

26.

Maurice JB, Garvey L, Tsochatzis EA, Wiltshire M, Cooke G, Guppy N, et al. Monocyte-macrophage activation is associated with nonalcoholic fatty liver disease and liver fibrosis in HIV monoinfection independently of the gut microbiome and bacterial translocation. AIDS. 2019;33(5):805–14.PubMedCrossRef

27.

Zhou X, Li J, Guo J, Geng B, Ji W, Zhao Q, et al. Gut-dependent microbial translocation induces inflammation and cardiovascular events after ST-elevation myocardial infarction. Microbiome. 2018;6(1):66.PubMedPubMedCentralCrossRef

28.

Kallio KAE, Hätönen KA, Lehto M, Salomaa V, Männistö S, Pussinen PJ. Endotoxemia, nutrition, and cardiometabolic disorders. Acta Diabetol. 2015;52(2):395–404.PubMedCrossRef

29.

Tang WHW, Bäckhed F, Landmesser U, Hazen SL. Intestinal microbiota in cardiovascular health and disease. J Am Coll Cardiol. 2019;73(16):2089–105.PubMedPubMedCentralCrossRef

30.

Sandek A, Bauditz J, Swidsinski A, Buhner S, Weber-Eibel J, von Haehling S, et al. Altered intestinal function in patients with chronic heart failure. J Am Coll Cardiol. 2007;50(16):1561–9.PubMedCrossRef

31.

Srinivasa S, Fitch KV, Lo J, Kadar H, Knight R, Wong K, et al. Plaque burden in HIV-infected patients is associated with serum intestinal microbiota-generated trimethylamine. AIDS. 2015;29(4):443–52.PubMedPubMedCentralCrossRef

32.

Haissman JM, Knudsen A, Hoel H, Kjaer A, Kristoffersen US, Berge RK, et al. Microbiota-dependent marker TMAO is elevated in silent ischemia but is not associated with first-time myocardial infarction in HIV infection. J Acquir Immune Defic Syndr. 2016;71(2):130–6.PubMedCrossRef

33.

Kelesidis T, Kendall MA, Yang OO, Hodis HN, Currier JS. Biomarkers of microbial translocation and macrophage activation: association with progression of subclinical atherosclerosis in HIV-1 infection. J Infect Dis. 2012;206(10):1558–67.PubMedPubMedCentralCrossRef

34.

Longenecker CT, Jiang Y, Orringer CE, Gilkeson RC, Debanne S, Funderburg NT, et al. Soluble CD14 is independently associated with coronary calcification and extent of subclinical vascular disease in treated HIV infection. AIDS. 2014;28(7):969–77.PubMedPubMedCentralCrossRef

35.

Ancuta P, Kamat A, Kunstman KJ, Kim E-Y, Autissier P, Wurcel A, et al. Microbial translocation is associated with increased monocyte activation and dementia in AIDS patients. PLoS One. 2008;3(6):e2516.PubMedPubMedCentralCrossRef

36.

Lyons JL, Uno H, Ancuta P, Kamat A, Moore DJ, Singer EJ, et al. Plasma sCD14 is a biomarker associated with impaired neurocognitive test performance in attention and learning domains in HIV infection. J Acquir Immune Defic Syndr. 2011;57(5):371–9.PubMedPubMedCentralCrossRef

37.

Muñoz-Nevárez LA, Imp BM, Eller MA, Kiweewa F, Maswai J, Polyak C, et al. Monocyte activation, HIV, and cognitive performance in East Africa. J Neurovirol. 2020;26(1):52–9.PubMedCrossRef

38.

Krebs SJ, Slike BM, Sithinamsuwan P, Allen IE, Chalermchai T, Tipsuk S, et al. Sex differences in soluble markers vary before and after the initiation of antiretroviral therapy in chronically HIV-infected individuals. AIDS. 2016;30(10):1533–42.PubMedPubMedCentralCrossRef

39.

Imp BM, Rubin LH, Tien PC, Plankey MW, Golub ET, French AL, et al. Monocyte activation is associated with worse cognitive performance in virologically suppressed HIV-infected women. J Infect Dis. 2016;2016:jiw506.

40.

Royal W 3rd, Cherner M, Burdo TH, Umlauf A, Letendre SL, Jumare J, et al. Associations between cognition, gender and monocyte activation among HIV infected individuals in Nigeria. PLoS One. 2016;11(2):e0147182.PubMedPubMedCentralCrossRef

41.

Kamkwalala AR, Wang X, Maki PM, Williams DW, Valcour VG, Damron A, et al. Brief report: higher peripheral monocyte activation markers are associated with smaller frontal and temporal cortical volumes in women with HIV. J Acquir Immune Defic Syndr. 2020;84(1):54–59.

42.

Gianella S, Letendre SL, Iudicello J, Franklin D, Gaufin T, Zhang Y, et al. Plasma (1 → 3)-β-D-glucan and suPAR levels correlate with neurocognitive performance in people living with HIV on antiretroviral therapy: a CHARTER analysis. J Neurovirol. 2019;25(6):837–43.PubMedPubMedCentralCrossRef

43.

Hoenigl M, de Oliveira MF, Pérez-Santiago J, Zhang Y, Morris S, McCutchan AJ, et al. (1→3)-β-D-Glucan levels correlate with neurocognitive functioning in HIV-infected persons on suppressive antiretroviral therapy: a cohort study. Medicine. 2016;95(11):e3162.PubMedPubMedCentralCrossRef

44.

Tuddenham SA, Koay WLA, Zhao N, White JR, Ghanem KG, Sears CL, et al. The impact of human immunodeficiency virus infection on gut microbiota α-diversity: an individual-level meta-analysis. Clin Infect Dis. 2020;70(4):615–27.PubMedCrossRef

45.

Pase MP, Himali JJ, Beiser AS, DeCarli C, McGrath ER, Satizabal CL, et al. Association of CD14 with incident dementia and markers of brain aging and injury. Neurology. 2020;94(3):e254–e66.PubMedPubMedCentralCrossRef

46.

Michelini Z, Baroncelli S, Fantauzzi A, Pasquale C, Galluzzo CM, Sanchez M, et al. Reduced plasma levels of sCD14 and I-FABP in HIV-infected patients with mesalazine-treated ulcerative colitis. HIV Clin Trials. 2016;17(2):49–54.PubMedCrossRef

47.

Munford RS. Endotoxemia-menace, marker, or mistake? J Leukoc Biol. 2016;100(4):687–98.PubMedPubMedCentralCrossRef

Titel: Gastrointestinal Dysfunction and HIV Comorbidities
verfasst von: Jae H. Sim
Shibani S. Mukerji
Samuel C. Russo
Janet Lo
Publikationsdatum: 19.01.2021
Verlag: Springer US
Erschienen in: Current HIV/AIDS Reports / Ausgabe 1/2021
Print ISSN: 1548-3568
Elektronische ISSN: 1548-3576
DOI: https://doi.org/10.1007/s11904-020-00537-8

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Gastrointestinal Dysfunction and HIV Comorbidities

Abstract

Purpose of Review

Recent Findings

Summary

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2021

Patient-Led Decision-Making for HIV Preexposure Prophylaxis

Aging with HIV in Latin America and the Caribbean: a Systematic Review

Immune Dysregulation in Myocardial Fibrosis, Steatosis, and Heart Failure: Current Insights from HIV and the General Population

Non-communicable Diseases in Pregnant and Postpartum Women Living with HIV: Implications for Health Throughout the Life Course

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin